MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Launched by UNIVERSITY OF CHICAGO · Jan 25, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new software developed by researchers at the University of Chicago that helps doctors analyze MRI images of the prostate. The goal is to improve the diagnosis of prostate cancer by using targeted biopsies, which are procedures where small samples of tissue are taken from the prostate to check for cancer. If you are a male between the ages of 65 and 74 and have been referred for an MRI due to suspected prostate cancer, you may be eligible to participate in this study.

Participants will need to undergo one MRI scan and 1-2 biopsies over the course of about 12 months, during which the researchers will monitor your progress. To join the study, you must provide written consent and be able to understand the process. However, individuals who cannot give consent, those with certain psychiatric disorders, prisoners, or minors cannot participate. This trial aims to enhance the way doctors diagnose prostate cancer, ultimately leading to better treatment outcomes for patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
• • Voluntary written informed consent before the MRI examination.
• Exclusion Criteria:
• • Subjects incapable of giving informed written consent.
• • Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
• • Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
• • Prisoners.
• • Minor children (under the age of 18 years old).
• • Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.